Melanoma patients with brain metastasis had decreased STAT3 activation and increased PD-L1 levels in sEVs as compared to patients without brain metastasis, possibly because of systemic immunosuppression in melanoma brain metastasis patients. This evidence concerns the gene STAT3 and melanoma.